Medical Pharmacology

Uzm. Dr. Mert Kaşkal

HypertensionHeart FailureCardiovascular DiseasesAtrial FibrillationMyocardial InfarctionCOVID-19

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Hypertension 4 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Heart Failure 3 publications
  • Cardiovascular Diseases 3 publications
  • Atrial Fibrillation 2 publications
  • Myocardial Infarction 2 publications
  • COVID-19 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Pharmacologysaglik.gov.trFrom source
  • InstitutionMarmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesisaglik.gov.trFrom source
  • Area of workHypertensionExtracted from 4 publications · Model version —From source
  • Publications42 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-2220-8529ORCIDFrom source
  • Last synchronised5 November 2026 10:37https://marmaraeah.saglik.gov.tr/TR-1393577/doktorlarimiz.html#mert-kaskalsaglik.gov.tr

Scientific work

Publications on Hypertension

42 publications
  1. Cytotoxic effect of famotidine in breast adenocarcinoma cells line

    Northern Clinics of Istanbul, 2026

    DOI 10.14744/nci.2026.55899 PMID 41940059 Open-access full textSource: OpenAlex

  2. Cross-exclusion of patients with chronic obstructive pulmonary disease and heart failure in randomized controlled drug trials

    Respiratory Medicine, 2026

    DOI 10.1016/j.rmed.2026.108781 PMID 41862104 Source: ORCID

  3. Albumin levels and risk of early cardiovascular complications after endovascular thrombectomy for acute ischaemic stroke

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-50280-0 PMID 42032112 Open-access full textSource: ORCID

  4. Long-term prognosis in Takotsubo syndrome compared to heart failure: observations from a global federated research network

    ESC Heart Failure, 2026

    DOI 10.1093/eschf/xvag065 PMID 41761829 2 citations (Europe PMC) Open-access full textSource: ORCID

  5. Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    BMC Pulmonary Medicine, 2026

    DOI 10.1186/s12890-026-04216-z PMID 41782097 Open-access full textSource: ORCID

  6. Prognostic Impact of New-Onset Atrial Fibrillation After Cardiac Arrest: Observations From a Federated Research Network

    Journal of Cardiovascular Electrophysiology, 2026

    DOI 10.1111/jce.70288 PMID 41668553 Open-access full textSource: ORCID

  7. Additional file 2 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985912 Open-access full textSource: OpenAlex

  8. Additional file 1 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985909 Open-access full textSource: OpenAlex

  9. Additional file 6 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985924 Open-access full textSource: OpenAlex

  10. Additional file 7 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985927 Open-access full textSource: OpenAlex

View all 42 publications